| 包装: | 1mg |
| 规格: | 98% |
| 市场价: | 5556元 |
| 分子量: | 311.1 |
Background:
Dichlorphenamide-13C6is intended for use as an internal standard for the quantification of dichlorphenamide by GC- or LC-MS. Dichlorphenamide is a sulfonamide and an orally bioavailable carbonic anhydrase (CA) inhibitor (Kis = 1.20, 38, 50, and 50 nM for the human CA isoforms CAI, CAII, CAIX, and CAXII, respectively).1It lowers intraocular pressure in rabbits when 50 µl of a 10% solution is applied topically to the eye.2Dichlorphenamide rescues the potassium deficiency and prevents insulin-induced paralysis in a rat model of familial hypokalemic periodic paralysis when administered at a dose of 5.6 mg/kg per day for ten days.3Formulations containing dichlorphenamide have been used in the treatment of glaucoma and primary periodic paralysis.
1.Brzozowski, Z., Slawi?ski, J., Innocenti, A., et al.Carbonic anhydrase inhibitors. Regioselective synthesis of novel 1-substituted 1,4-dihydro-4-oxo-3-pyridinesulfonamides and their inhibition of the human cytosolic isozymes I and II and transmembrane cancer-associated isozymes IX and XIIEur. J. Med. Chem.45(9)3656-3661(2010) 2.Lotti, V.J., Schmitt, C.J., and Gautheron, P.D.Topical ocular hypotensive activity and ocular penetration of dichlorphenamide sodium in rabbitsGraefes Arch. Clin. Exp. Ophthalmol.222(1)13-19(1984) 3.Tricarico, D., Mele, A., and Conte Camerino, D.Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channelsNeuromuscul. Disord.16(1)39-45(2006)
m.cnreagent.com